Last reviewed · How we verify
2007-2008 Influenza Virus Vaccine
At a glance
| Generic name | 2007-2008 Influenza Virus Vaccine |
|---|---|
| Also known as | Fluzone® |
| Sponsor | Sanofi Pasteur, a Sanofi Company |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Efficacy Study of Two Influenza Vaccines and Placebo in Healthy Adult Subjects (PHASE3)
- Influenza Vaccine in Lung Transplant Patients - Seroprotection
- Influenza Vaccine in Lung Transplant Patients - Persistence of Antibodies
- Influenza Vaccine in Lung Transplant Patients - Persistence of Antibodies Beyond the Season
- A Randomized Study to Compare the Safety and Immunogenicity of Fluviral® Made With New Versus Aged Bulk (PHASE4)
- Non-Inferiority of Various GSK Bio's Influenza Vaccine Presentations in Adults Aged 65 Years and Over (PHASE2)
- Immunogenicity of a Surface Antigen, Inactivated Influenza Vaccine Formulation 2007-2008 (PHASE2)
- Support Annual Strain Update, Safety and Immunogenicity of an Inactivated, Adjuvanted Influenza Vaccine, Formulation 2007-2008, When Administered to Subjects 18-64 Years Affected by Chronic Diseases. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 2007-2008 Influenza Virus Vaccine CI brief — competitive landscape report
- 2007-2008 Influenza Virus Vaccine updates RSS · CI watch RSS
- Sanofi Pasteur, a Sanofi Company portfolio CI